Vernalis Research represents the research activities of Vernalis plc. With a team experienced in fragment- and structure-based drug discovery since 1997, Vernalis Research has been committed to growing its external research collaborations. External endorsement of its discovery capabilities comes from major pharma companies around the world and includes Novartis, Servier, GSK, Lundbeck, Genentech, Asahi Kasei Pharma and Taisho. Our strengths are in developing and applying the most appropriate fragment- and structure-based methods to work with our partners to solve problems in drug discovery.
With 6 development candidates generated in the past 6 years and cell active lead compounds against 15 targets, the team has worked towards repeating the recent success for internally initiated programmes such as V158866 against FAAH, for the management of neuropathic pain and V158411 against Chk1, for cancer.
For further information visit us at www.vernalis-research.com.